What's in a name?

  title={What's in a name?},
  author={Arnold I. Caplan},
  journal={Tissue engineering. Part A},
  volume={16 8},
  • A. Caplan
  • Published 2010
  • Biology
  • Tissue engineering. Part A
Dear Editor: In the late 1980s, I coined the name ‘‘mesenchymal stem cell’’ (MSC) to provocatively emphasize that multi-lineage progenitor cells could be isolated and culture-expanded from human adult bone marrow. The studies from our lab and others provided the basis for the hypothesis diagram pictured in Figure 1. The appropriate acronym, MSC, was generally accepted, and the use of this term eventually resulted in a consensus paper that further strengthened the use of MSC for this class of… 

Figures from this paper

Mesenchymal stem cells – a historical overview

A historical perspective concerning studies on MSCs, controversies regarding their name and their characteristics and clinical utilization are focused on.

Nomenclature and heterogeneity: consequences for the use of mesenchymal stem cells in regenerative medicine

Some consequences of the nomenclature debate and heterogeneity of MSCs are examined, emphasizing that product development should prioritize detailed characterization of therapeutic cell populations for specific indications.

The majority of cells in so-called "mesenchymal stem cell" population are neither stem cells nor progenitors.

Mesenchymal stem cells: Cell therapy and regeneration potential

The characteristics of MSCs are discussed and it is suggested that the variations in their distinctive features are dependent on the source and method of isolation as well as epigenetic changes during maintenance and growth.

Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors

The extent of characterisation was poor and variable, and concur with those in other fields including bone marrow aspirate and platelet-rich plasma therapy.

Niches for Skeletal Stem Cells of Mesenchymal Origin

The current scientific literature on stem cell niches for the SSPCs identified so far are summarized and potential factors and environmental cues of importance in these niches in vivo are discussed.

There Is No "Stem Cell Mess".

  • A. Caplan
  • Biology, Engineering
    Tissue engineering. Part B, Reviews
  • 2019
This comment emphasizes the important distinction that MSCs are not stem cells and the name change to Medicinal Signaling Cells.

Is Stem Cell Commerce in Small Animal Therapies Scientifically and Morally Justified?

The scientific challenges of mesenchymal stem cell therapy in veterinary regenerative medicine are discussed, and published trials of adipose-tissue-derived stem cells in companion animal diseases that spontaneously occur are reviewed.

Tissue Engineering: Then, Now, and the Future.

  • A. Caplan
  • Biology
    Tissue engineering. Part A
  • 2019
This "invited submission" concisely reviews the author's involvement in the early era of tissue engineering and summarizes his perspective and points out the journal was present in this early era.

Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use

In the authors' opinion, mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 pneumonia, due to the broad pharmacological effects it shows, including anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties.



All MSCs are pericytes?

Mesenchymal Stem Cells

The bone marrow contains multipotent MSC, which can be easily isolated and cultured in vitro, and the possibility of their clinical use in cell and gene therapy is analyzed.

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC, believing this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.

The mesengenic process.

  • A. Caplan
  • Biology
    Clinics in plastic surgery
  • 1994

A perivascular origin for mesenchymal stem cells in multiple human organs.

New era of cell-based orthopedic therapies.

  • A. Caplan
  • Biology, Medicine
    Tissue engineering. Part B, Reviews
  • 2009
It is now apparent that MSCs are pericytes (cells that surround blood vessels) throughout the body, thus allowing allogeneic M SCs to be infused into patients requiring clinically relevant treatments and usher in a new era of cell-based therapies.

Cytokine expression by human marrow‐derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL‐1α

The identification of a cytokine expression profile under standardized growth medium conditions and in the presence of regulators of the osteogenic and stromal cell lineages is interpreted to suggest that mesenchymal progenitor cells derived from human bone marrow serve specific supportive functions in the microenvironment of bone marrow.

Mesenchymal stem cells as trophic mediators

Several studies which tested the use of MSCs in models of infarct (injured heart), stroke (brain), or meniscus regeneration models are reviewed within the context of M SC‐mediated trophic effects in tissue repair.

Human mesenchymal stem cells modulate allogeneic immune cell responses.

Insight is offered into the interactions between allogeneic MSCs and immune cells and mechanisms likely involved with the in vivo MSC-mediated induction of tolerance that could be therapeutic for reduction of GVHD, rejection, and modulation of inflammation.

Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosis

It is demonstrated that human bone marrow‐derived MSCs (BM‐hMSCs) promote functional recovery in both chronic and relapsing‐remitting models of mouse EAE, and their ability to modulate disease progression and the host immune response is tested.